1331 related articles for article (PubMed ID: 12855635)
21. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
22. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
23. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
[TBL] [Abstract][Full Text] [Related]
24. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors.
Gallant MA; Samadfam R; Hackett JA; Antoniou J; Parent JL; de Brum-Fernandes AJ
J Bone Miner Res; 2005 Apr; 20(4):672-81. PubMed ID: 15765187
[TBL] [Abstract][Full Text] [Related]
25. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation.
Nagai M; Sato N
Biochem Biophys Res Commun; 1999 Apr; 257(3):719-23. PubMed ID: 10208850
[TBL] [Abstract][Full Text] [Related]
26. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
27. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
28. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.
Liu XH; Kirschenbaum A; Yao S; Liu G; Aaronson SA; Levine AC
Cancer Res; 2007 Jun; 67(12):5747-53. PubMed ID: 17575141
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer mediates osteoclastogenesis through two different pathways.
Inoue H; Nishimura K; Oka D; Nakai Y; Shiba M; Tokizane T; Arai Y; Nakayama M; Shimizu K; Takaha N; Nonomura N; Okuyama A
Cancer Lett; 2005 Jun; 223(1):121-8. PubMed ID: 15890244
[TBL] [Abstract][Full Text] [Related]
30. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
Wang L; Liu S; Quarles LD; Spurney RF
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
[TBL] [Abstract][Full Text] [Related]
31. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
32. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
33. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
Dorai T; Dutcher JP; Dempster DW; Wiernik PH
Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
[TBL] [Abstract][Full Text] [Related]
36. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.
Chikatsu N; Takeuchi Y; Tamura Y; Fukumoto S; Yano K; Tsuda E; Ogata E; Fujita T
Biochem Biophys Res Commun; 2000 Jan; 267(2):632-7. PubMed ID: 10631114
[TBL] [Abstract][Full Text] [Related]
37. Dental cells express factors that regulate bone resorption.
Rani CS; MacDougall M
Mol Cell Biol Res Commun; 2000 Mar; 3(3):145-52. PubMed ID: 10860862
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
Corey E; Quinn JE; Bladou F; Brown LG; Roudier MP; Brown JM; Buhler KR; Vessella RL
Prostate; 2002 Jun; 52(1):20-33. PubMed ID: 11992617
[TBL] [Abstract][Full Text] [Related]
39. Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells.
Zahanich I; Graf EM; Heubach JF; Hempel U; Boxberger S; Ravens U
J Bone Miner Res; 2005 Sep; 20(9):1637-46. PubMed ID: 16059635
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]